Deltagen Inc. DGEN

Company Overview

DeltaGen, Inc. (formerly NASDAQ: DGEN) was a U.S.-based biotechnology company focused on functional genomics, drug discovery, and the development of genetically engineered mouse models used in pharmaceutical research. The company operated within the broader biotechnology and life sciences tools industries, serving pharmaceutical companies, academic research institutions, and biotechnology firms engaged in therapeutic target discovery and preclinical development.

DeltaGen’s primary business activities centered on identifying gene functions and validating drug targets through large-scale mouse genetics programs and bioinformatics capabilities. Its proprietary platforms included genetically modified mouse models and genomics databases intended to accelerate pharmaceutical research. Historically, the company positioned itself as a specialized genomics research provider during the expansion of post-Human Genome Project drug discovery efforts in the late 1990s and early 2000s. Publicly available records indicate that the company underwent financial restructuring and strategic changes prior to its eventual acquisition. Certain operational details from later periods are limited in current public disclosures, and some historical data is inconclusive based on available public sources.